Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.49 |
| ▸ | CCR9 | P51686 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981244 | 0.85 | PIK3CD (0.49) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2976044 | 0.85 | CCR9 (0.51) | HSD17B2CCR9 | |
| SCHEMBL2975323 | 0.81 | CCR9 (0.48) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2972098 | 0.77 | CCR9 (0.48) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2977421 | 0.77 | HSD17B2 (0.49) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2978292 | 0.77 | CCR9 (0.52) | HSD17B2CCR9 | |
| SCHEMBL2979475 | 0.77 | CCR9 (0.51) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2971727 | 0.76 | CCR9 (0.50) | HSD17B2CCR9 | |
| SCHEMBL2969082 | 0.75 | HSD17B2 (0.55) | PIK3CDHSD17B2CCR9 | |
| SCHEMBL2980119 | 0.74 | CCR9 (0.58) | HSD17B2CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835468-B2 | N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides | CHEMOCENTRYX, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245138-A1 | N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES | CCR9, CCR2, CCR10 | PIK3CD 4215/4885HSD17B2 1177/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.